Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4560425 | 1.00 | TYMP (0.56) | TYMPNPC1ATAD2GDALMNA | |
| SCHEMBL5163518 | 0.74 | TYMP (0.48) | TYMPNPC1ATAD2GDALMNA | |
| SCHEMBL31376425 | 0.74 | TYMP (0.54) | TYMPATAD2GDACA1PNP | |
| SCHEMBL10021065 | 0.73 | PDE3B (0.45) | TYMPALDH1A1KMT2APDE3BPDE3A | |
| SCHEMBL2888237 | 0.72 | TYMP (0.52) | TYMPNPC1LMNAPDE3BPDE3A | |
| SCHEMBL4560955 | 0.72 | TYMP (0.52) | TYMPNPC1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL4560171 | 0.72 | TYMP (0.52) | TYMPNPC1ATAD2GDALMNA | |
| SCHEMBL2891489 | 0.72 | TYMP (0.52) | TYMPNPC1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL13932516 | 0.72 | TYMP (0.41) | TYMPNPC1ATAD2GDALMNA | |
| SCHEMBL4561126 | 0.72 | TYMP (0.52) | TYMPNPC1LMNAPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | claimed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | claimed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | claimed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | claimed |
| US-7132229-B2 | Photothermographic material and image forming method | FUJI PHOTO FILM CO., LTD (JP) | 2006-11-07 | — | — | US | claimed |
| US-20060019207-A1 | Photothermographic material and image forming method | FUJIFILM CORPORATION (JP) | 2006-01-26 | — | — | US | claimed |
| US-12552882-B2 | Polymeric disinfectants and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2026-02-17 | — | — | US | disclosed |
| EP-4237493-B1 | POLYMERIC DISINFECTANTS AND USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-12-10 | — | — | EP | disclosed |
| US-20250361558-A1 | THIRD DNA BASE PAIR SITE-SPECIFIC DNA DETECTION | ILLUMINA INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| US-4207416-A | ANTITUMOR AGENTS | ENGELHARD MINERALS & CHEMICALS CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| US-4113949-A | GERMICIDES | PCR, INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4080324-A | ANTITUMOR AGENTS | ENGELHARD MINERALS & CHEMICALS CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-3954758-A | GERMICIDES, CANCER CHEMOTHERAPY | PCR, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | TYMP 2346/4885NPC1 3507/4885ATAD2 2972/4885 |
| US-12552882-B2 | Polymeric disinfectants and uses thereof | PIK3C3, POLR1C, CUTA | TYMP 4415/4885NPC1 4776/4885ATAD2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.